India’s Pricing Tussle Escalates After Regulator Names “Overcharging” Firms
Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.
You may also be interested in...
India’s apex pricing authority concludes some in Rx industry have not played 'fair'; 25% of products show market failure, Bhupendra Singh says.
2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.
Draft appears set for rocky path ahead; Pink Sheet highlights five controversial elements ahead of Aug 30 stakeholders meeting.